Regeneron Pharmaceuticals (REGN) Revenue (2009 - 2026)

Regeneron Pharmaceuticals' Revenue history runs 18 years deep, the most recent figure standing at $3.6 billion for Q1 2026.

• On a quarterly basis, Revenue rose 19.04% year-over-year to $3.6 billion in Q1 2026; TTM through Mar 2026 was $14.9 billion, a 5.92% increase from a year earlier, with the FY2025 full-year figure at $14.3 billion, up 0.99% from the prior year.
• Revenue declined to $3.6 billion in Q1 2026 per REGN's latest filing, from $3.9 billion in the prior quarter.
• Across five years, Revenue topped out at $3.9 billion in Q4 2025 and bottomed at $50.0 million in Q1 2022.
• The 5-year median for Revenue is $3.4 billion (2023), against an average of $3.0 billion.
• Across the five-year window, Revenue slumped 98.02% in 2022 and soared 6224.2% in 2023, its largest moves.
• Year by year, Revenue stood at $100.0 million in 2022, then surged by 3334.3% to $3.4 billion in 2023, then gained by 10.33% to $3.8 billion in 2024, then gained by 2.51% to $3.9 billion in 2025, then declined by 7.18% to $3.6 billion in 2026.
• Per Business Quant, the three latest REGN Revenue figures stand at $3.6 billion (Q1 2026), $3.9 billion (Q4 2025), and $3.8 billion (Q3 2025).